Leading up to the Supreme Court's decision in the case of King v. Burwell, Avik Roy, senior fellow at the Manhattan Institute, discusses in what ways Congress should potentially act if the plaintiffs receive a favorable ruling, who is to blame more if subsidies are removed from the federal marketplace, and how much time there will be for a patch to prevent millions of Americans losing financial assistance and subsequently their health insurance.
Leading up to the Supreme Court's decision in the case of King v. Burwell, Avik Roy, senior fellow at the Manhattan Institute, discusses in what ways Congress should potentially act if the plaintiffs receive a favorable ruling, who is to blame more if subsidies are removed from the federal marketplace, and how much time there will be for a patch to prevent millions of Americans losing financial assistance and subsequently their health insurance.
Mr Roy lays the blame for the negative effects that will ensue should the Supreme Court rule in favor of the plaintiffs on both the Obama administration and the Republicans. The adminisrtation is at fault for even creating the situation in the first place, but since Republicans now control Congress, if they do nothing they will be responsible for the outcome.
"So the question is, 'Can Republicans agree on how to [minimize the disruption]?'" he explained. "Because there are different schools of thought. Some conservatives say, 'Don't do anything. Let the disruption happen, it's not our fault.' Others say, 'Well, listen we control the legislative branch, it's up to us to try to come up with a way to handle this problem.'"
Health Care Utilization and Cost of Diagnostic Testing for Respiratory Infections
September 17th 2025Syndromic reverse transcriptase–polymerase chain reaction tests for respiratory infections were associated with lower health care resource utilization and costs, implicating potential for improved value in patient care.
Read More
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More